advertisement
Ye J 24
Showing records 1 to 24 | Display all abstracts from Ye J99353 A Structure-Related Fine-Grained Deep Learning System With Diversity Data for Universal Glaucoma Visual Field Grading
Huang X
Frontiers in medicine 2022; 9: 832920
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Fang F
Molecular Therapy 2022; 30: 1421-1431
98852 Posterior scleral contraction to treat myopic traction maculopathy at different stages
Zhu S
American journal of translational research 2022; 14: 389-395
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Zhuang P
Molecular Therapy 2022; 30: 1421-1431
98852 Posterior scleral contraction to treat myopic traction maculopathy at different stages
Xue A
American journal of translational research 2022; 14: 389-395
99353 A Structure-Related Fine-Grained Deep Learning System With Diversity Data for Universal Glaucoma Visual Field Grading
Jin K
Frontiers in medicine 2022; 9: 832920
98852 Posterior scleral contraction to treat myopic traction maculopathy at different stages
Li H
American journal of translational research 2022; 14: 389-395
99353 A Structure-Related Fine-Grained Deep Learning System With Diversity Data for Universal Glaucoma Visual Field Grading
Zhu J
Frontiers in medicine 2022; 9: 832920
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Feng X
Molecular Therapy 2022; 30: 1421-1431
99353 A Structure-Related Fine-Grained Deep Learning System With Diversity Data for Universal Glaucoma Visual Field Grading
Xue Y
Frontiers in medicine 2022; 9: 832920
98852 Posterior scleral contraction to treat myopic traction maculopathy at different stages
Ye J
American journal of translational research 2022; 14: 389-395
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Liu P
Molecular Therapy 2022; 30: 1421-1431
98852 Posterior scleral contraction to treat myopic traction maculopathy at different stages
Pan A
American journal of translational research 2022; 14: 389-395
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Liu D
Molecular Therapy 2022; 30: 1421-1431
99353 A Structure-Related Fine-Grained Deep Learning System With Diversity Data for Universal Glaucoma Visual Field Grading
Si K; Zhang C
Frontiers in medicine 2022; 9: 832920
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Huang H
Molecular Therapy 2022; 30: 1421-1431
98852 Posterior scleral contraction to treat myopic traction maculopathy at different stages
Zheng J
American journal of translational research 2022; 14: 389-395
99353 A Structure-Related Fine-Grained Deep Learning System With Diversity Data for Universal Glaucoma Visual Field Grading
Meng S
Frontiers in medicine 2022; 9: 832920
98852 Posterior scleral contraction to treat myopic traction maculopathy at different stages
Xu G
American journal of translational research 2022; 14: 389-395
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Li L
Molecular Therapy 2022; 30: 1421-1431
99353 A Structure-Related Fine-Grained Deep Learning System With Diversity Data for Universal Glaucoma Visual Field Grading
Gong W
Frontiers in medicine 2022; 9: 832920
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Chen W; Liu L
Molecular Therapy 2022; 30: 1421-1431
99353 A Structure-Related Fine-Grained Deep Learning System With Diversity Data for Universal Glaucoma Visual Field Grading
Ye J
Frontiers in medicine 2022; 9: 832920
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Sun Y; Jiang H; Ye J; Hu Y
Molecular Therapy 2022; 30: 1421-1431
